Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 14, 2003. The report details specific corporate actions regarding share re-purchases and changes in directors' interests in the company's Ordinary Shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to a specific share transaction:
- Share Re-purchase Price: 1023.2984p per share.
- Shares Purchased for Cancellation: 350,000 ordinary shares.
Material Changes
The filing reports the following material corporate actions:
- Share Re-purchase: On March 13, 2003, the company purchased 350,000 ordinary shares for cancellation in accordance with shareholder authority granted at the Annual General Meeting on May 20, 2002.
- Directors' Interests (March 12): The GSK Trust transferred 3,846 Ordinary Shares to a participant of the Glaxo Wellcome 1999 Long Term Incentive Plan.
- Directors' Interests (March 13): The GSK Trust transferred 15,934 Ordinary Shares to participants of the Glaxo Wellcome 1999 Long Term Incentive Plan.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risks, contingencies, or unusual items beyond the routine disclosure of share transactions and trust transfers.
Investor Verification Checklist
- Verify the total number of shares remaining after the cancellation of 350,000 shares.
- Confirm the total cost of the re-purchase transaction (350,000 shares at 1023.2984p).
- Review the full details of the Glaxo Wellcome 1999 Long Term Incentive Plan to understand the impact of the trust transfers on director holdings.
- Check subsequent filings for the impact of these share cancellations on earnings per share (EPS).